ICH Q4B: Harmonized Doesn't Mean Interchangeable Yet

ICH harmonization gets treated as a finish line: once a general chapter is described as “ICH-harmonized,” teams assume the USP, Ph. Eur., and JP versions are interchangeable wherever they file. ICH Q4B says otherwise. The guideline runs each pharmacopoeial text through a region-by-region evaluation and records the actual outcome in a topic-specific annex — and only one of its three possible outcomes means what most CMC teams assume harmonization already means.

What Q4B actually evaluates

The Pharmacopoeial Discussion Group — USP, the European Pharmacopoeia, and the Japanese Pharmacopoeia — works to align the text of shared general chapters. Q4B is the separate ICH process that asks a narrower question about the result: can a sponsor use any one region's version of that specific chapter interchangeably across all three ICH regions without additional regional testing? The Q4B Expert Working Group evaluates each candidate chapter and issues a topic-specific annex recording what it found, and each annex then moves through its own Steps 2 through 5, with regions implementing on their own timelines. None of this substitutes for validating the method itself under ICH Q2(R2) or developing it under ICH Q14 — Q4B answers a cross-region interchangeability question, not a method-validity one.

Three outcomes, only one of them unconditional

Treating “harmonized” as synonymous with “interchangeable” skips the step that actually matters: reading what the specific annex concluded. The dissolution test annex is a useful illustration — its interchangeability finding does not hold unconditionally across every test configuration; certain media conditions fall outside it, which means a sponsor relying on the dissolution general chapter still has to check whether their specific method sits inside or outside the annex's stated conditions before assuming it travels across regions untouched.

• Interchangeable. The annex concludes a sponsor may rely on any one ICH region's version of the chapter without additional regional testing.
• Interchangeable with stated conditions. The chapter is interchangeable only within conditions the annex specifies — a particular apparatus, media, or test parameter outside of which the finding does not apply.
• Not interchangeable. The regional versions diverge enough that a sponsor still needs the specific pharmacopoeial version governing each region they file in.

Interchangeable is an annex-specific finding, not a property of the word "harmonized." One doesn't imply the other. Why the annex, not the headline, controls

The annex list still has gaps

Q4B is not a finished project. New annexes have continued reaching Step 4 for close to two decades after the 2007 core guideline, which means the evaluated-chapter list keeps growing rather than sitting fixed. The practical consequence: plenty of commonly cited compendial tests have no Q4B annex at all. That is not an interchangeability finding in a sponsor's favor — it means Q4B has simply never weighed in, and the specification still has to trace to whichever pharmacopoeia governs each filing region, the same as if the harmonization initiative did not exist for that chapter. Specifications built under ICH Q6A/Q6B logic should name the governing pharmacopoeial edition explicitly rather than citing a test as generically "compendial," precisely so this gap is visible when someone checks it.

This is a bounded piece of due diligence, and it is skipped for an understandable reason: "ICH-harmonized" sounds complete even when the governing annex says the opposite, or when no annex exists yet. Building the check into your CMC regulatory strategy — annex by annex, region by region, at the point specifications are set rather than when a reviewer asks — is what keeps a compendial assumption from becoming a deficiency response six months into a filing.